Golden H W, Iacuzio D A, Otterness I G
Department of Immunology and Infectious Diseases, Pfizer Central Research, Groton, CT 06340.
Agents Actions. 1987 Aug;21(3-4):371-4. doi: 10.1007/BF01966519.
Injection of purified porcine C5a into 24-hr basophil-rich cutaneous basophil hypersensitivity sites in the dose range 10(-12)-10(-10) moles/site produced cutaneous basophil anaphylaxis (CBA). The H1 antihistamine antagonist mepyramine, given orally (3.0-30 mg/kg), inhibited the vasopermeability, but not the basophil degranulation, characteristic of CBA. The antiallergy agent disodium cromoglycate (DSCG), administered intravenously (3.0-30 mg/kg), inhibited vasopermeability and basophil degranulation. DSCG inhibition of mast cell degranulation was not important in the inhibition of CBA, since intact mast cells were found to be depleted at basophil-rich sites and absent at C5a-induced CBA sites from animals treated with DSCG. C5a at 10(-11) moles/site also induced vasopermeability and mast cell degranulation in normal guinea pig skin. Vasopermeability, but not mast cell degranulation, was inhibited by mepyramine at 30 mg/kg p.o. However, DSCG at 10 mg/kg i.v. failed to inhibit either the vasopermeability or the mast cell degranulation of this reaction. These results indicate that C5a induces the degranulation of both basophils and mast cells in the guinea pig, and that C5a-induced degranulation of basophils, but not mast cells, is inhibited by DSCG.
将纯化的猪C5a以10(-12)-10(-10)摩尔/部位的剂量范围注射到富含嗜碱性粒细胞的24小时皮肤嗜碱性粒细胞超敏反应部位，可产生皮肤嗜碱性粒细胞过敏反应（CBA）。口服（3.0-30毫克/千克）H1抗组胺拮抗剂美吡拉敏可抑制CBA的血管通透性，但不抑制嗜碱性粒细胞脱颗粒。静脉注射（3.0-30毫克/千克）抗过敏剂色甘酸钠（DSCG）可抑制血管通透性和嗜碱性粒细胞脱颗粒。DSCG对肥大细胞脱颗粒的抑制在抑制CBA中并不重要，因为在用DSCG处理的动物的富含嗜碱性粒细胞的部位发现完整的肥大细胞已耗尽，而在C5a诱导的CBA部位则不存在。10(-11)摩尔/部位的C5a也可诱导正常豚鼠皮肤的血管通透性和肥大细胞脱颗粒。口服30毫克/千克的美吡拉敏可抑制血管通透性，但不抑制肥大细胞脱颗粒。然而，静脉注射10毫克/千克的DSCG未能抑制该反应的血管通透性或肥大细胞脱颗粒。这些结果表明，C5a可诱导豚鼠嗜碱性粒细胞和肥大细胞脱颗粒，并且DSCG可抑制C5a诱导的嗜碱性粒细胞脱颗粒，但不抑制肥大细胞脱颗粒。
